Patents Examined by Claire Kaufman
  • Bispecific EGFRvIII x CD3 antibody engaging molecules
    Patent number: 9249217
    Abstract: We have constructed bispecific antibody engaging molecules which have one arm that specifically engages a tumor cell which expresses the human EGFRvIII mutant protein on its surface, and a second arm that specifically engages T cell activation ligand CD3. The engaging molecules are highly cytotoxic and antigen-specific.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: February 2, 2016
    Assignees: Secretary, DHHS, Duke University
    Inventors: Darell D. Bigner, Chien-Tsun Kuan, John H. Sampson, Mingqing Cai, Bryan D. Choi, Ira H. Pastan
  • Method for producing antibody using “naked” expression vector expressing type II transmembrane fusion protein
    Patent number: 9234042
    Abstract: Methods are disclosed for generating antibodies and an expression vector used to express protein(s) which provoke the antibody response. The expression vector may be useful in generating an antibody directed to an antigen, comprising a gene in operable linkage with a promoter, which gene encodes upon expressing a fusion protein comprising (i) CD134L, a fragment or homologous protein thereof as N-terminal moiety of the fusion protein; and (ii) all or part of an antigenic protein as C-terminal moiety of the fusion protein. To generate the antibodies, the vector is injected into a subject animal, which produces a fusion protein, against which antibodies are generated.
    Type: Grant
    Filed: October 18, 2011
    Date of Patent: January 12, 2016
    Assignee: DELPHI GENETICS SA
    Inventors: Jean-Christophe Renauld, Muriel Lemaire, Laurie Dumoutier, Yannick Nizet, Alain Vanderplasschen, Laurent Gillet
  • Method of treatment of tumors that are resistant to EGFR antibody therapies by EGFR antibody cytotoxic agent conjugate
    Patent number: 9233171
    Abstract: The present invention relates to the identification that EGFR antibody immunoconjugates are effective in inhibiting the growth of tumor cells that have developed EGFR and/or ALK resistance mechanisms. Methods of administering the EGFR antibody immunoconjugates to patients having resistant tumor cells is also disclosed.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: January 12, 2016
    Assignee: ImmunoGen, Inc.
    Inventors: Julianto Setiady, Peter U. Park, Thomas Chittenden
  • TRAIL R2-specific multimeric scaffolds
    Patent number: 9212231
    Abstract: The present invention provides Tenascin-3 FnIII domain-based multimeric scaffolds that specifically bind to TRAIL Receptor 2 (TRAIL R2), a cell membrane receptor involved in apoptosis. The invention further provides engineered variants with increased affinity for the target, increased stability, and reduced immunogenicity. Furthermore, the present invention is related to engineered multivalent scaffolds as prophylactic, diagnostic, or therapeutic agents, and their uses against diseases caused by cells expressing TRAIL R2, in particular to a therapeutic use against cancer.
    Type: Grant
    Filed: April 12, 2011
    Date of Patent: December 15, 2015
    Assignee: MEDIMMUNE, LLC
    Inventors: Manuel Baca, Thomas Thisted, Jeffrey Swers, David Tice
  • Immunotherapy comprising TLR9 ligand and CD40 ligand
    Patent number: 9161976
    Abstract: The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: October 20, 2015
    Assignee: Trustees of Dartmouth College
    Inventors: Randolph J. Noelle, Cory L. Ahonen, Ross M. Kedl
  • Receptor-targeting reagents containing epidermal factor receptor-binding agents and IL-13 receptor-binding agents or IL-4 receptor-binding agents
    Patent number: 9155798
    Abstract: The present disclosure features, inter alia, receptor-targeting reagents (e.g., immunotoxic receptor-targeting reagents), methods of binding a receptor-targeting reagent to a cell and methods for treating a variety of disorders. Also featured are methods, compositions, and kits for selecting an appropriate treatment modality for a subject and/or treating a variety of disorders.
    Type: Grant
    Filed: August 25, 2008
    Date of Patent: October 13, 2015
    Assignee: Regents of the University of Minnesota
    Inventor: Daniel A. Vallera
  • EGFR-binding molecules and immunoconjugates thereof
    Patent number: 9125896
    Abstract: Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: September 8, 2015
    Assignee: ImmunoGen, Inc.
    Inventors: Julianto Setiady, Peter U. Park, Lingyun Rui, Thomas Chittenden, Gillian Payne
  • Anti-DR5 antibodies, polynucleotides and methods
    Patent number: 9127070
    Abstract: The present invention relates to an antibody which has a therapeutic effect on cancer, an autoimmune disease, or an inflammatory disease. That is, the present invention relates to an antibody which exhibits a cytotoxic activity against death domain-containing receptor-expressing cells through apoptosis. [Object] An object of the invention is to provide a pharmaceutical having a therapeutic effect on cancer. [Means for Resolution] A novel anti-DR5 antibody capable of inducing apoptosis in cells has more potent cytotoxic activity than currently available anti-DR5 antibodies.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: September 8, 2015
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Toshiaki Ohtsuka, Takeshi Takizawa, Akiko Oguni, Tatsuji Matsuoka, Hiroko Yoshida, Yumi Matsui
  • Combination of protein forms for hornfly vaccination
    Patent number: 9101557
    Abstract: Thrombostasin is an anti-clotting protein found in saliva of Haematobia irritans. Disclosed herein are studies testing blood uptake of horn flies feeding on cattle which confirm the association of ts genotype with blood uptake of horn flies. Blood uptake volumes of homozygous ts10 horn flies were lower than those of other ts genotypes when fed on control cattle. Cattle vaccinated with recombinant protein isoforms rTS9 or rTB8 resisted horn fly feeding by yielding lower blood volumes compared to flies feeding on control cattle. The impact of vaccination varied by ts genotype of flies. Cattle vaccinated with isoforms rTS9 resisted flies of ts2, ts9, and tb8 genotype. Vaccination with isoforms rTB8 produced resistance to ts8, ts9 and tb8 genotype flies. Horn flies of genotype ts10 were not affected with either TS isoforms and fed well on rTS9 and rTB9 vaccinated as on control-vaccinated cattle.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: August 11, 2015
    Assignee: Auburn University
    Inventors: Mary S. Cupp, Eddie W. Cupp, Christine Navarre, Dunhua Zhang, Latora W. Todd Jackson, Eugene Blair
  • TWEAK/Fn14 system regulates skeletal muscle atrophy and regeneration
    Patent number: 9068004
    Abstract: The invention provides methods for preventing loss and augmenting regeneration of skeletal muscle by decreasing the activity of the TWEAK/Fn14 system.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: June 30, 2015
    Assignee: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
    Inventor: Ashok Kumar
  • VEGF-activated trail ligands
    Patent number: 9056102
    Abstract: The present invention provides fusion proteins comprising an extracellular domain of a VEGF receptor and a death ligand. The fusion proteins bind to VEGF and to death receptors on tumor cells thereby inhibiting VEGF activation of VEGF receptors and inducing apoptosis in the tumor cells. Fusion proteins of the present invention are useful for inducing apoptosis and cytotoxic effects in cells, treating cancer and diseases or disorders related to unregulated angiogenesis and/or vasculogenesis. Thus, this invention further provides methods for treating angiogenesis related diseases using the fusion proteins, polynucleotides encoding the fusion proteins, vectors containing the polynucleotides, pharmaceutical compositions and kits containing the fusion proteins or the polynucleotides encoding the fusion proteins.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: June 16, 2015
    Assignee: The Regents of the University of California
    Inventor: Timothy P. Quinn
  • Humanized EGFR antibodies
    Patent number: 9051370
    Abstract: The present invention pertains to humanized anti-EGFR antibodies having antigen binding properties similar to those of the murine or chimeric anti-EGFR antibody from which they are derived. In particular, the present invention is directed to humanized anti-EGFR antibodies which are useful in the treatment of cancer.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: June 9, 2015
    Assignee: Glycotope GmbH
    Inventors: Steffen Goletz, Antje Danielczyk
  • Anti-DR4 agonist antibodies
    Patent number: 9044457
    Abstract: The present invention provides antibodies and antibody fragments that specifically recognize and agonize the death receptor 4 (DR4). Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: June 2, 2015
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Dimiter Dimitrov, Yang Feng
  • Cell death inhibition by macrophage migration inhibitory factor and a binding substance thereto
    Patent number: 9044483
    Abstract: The present invention relates to an antioxidant response element (ARE) activator comprising a macrophage migration inhibitory factor (MIF) or a modified form thereof, an ARE activator comprising a combination of MIF or a modified form thereof and a substance capable of binding to MIF, such as a 1,3-benzothiazinone, and so on. These ARE activators are useful.
    Type: Grant
    Filed: September 21, 2007
    Date of Patent: June 2, 2015
    Assignee: Takeda Pharmaceuticals Company Limited
    Inventor: Haruhide Kimura
  • Anti-EGFR antibody and use thereof
    Patent number: 9029513
    Abstract: A cell growth inhibitor that includes, as an antibody component, an artificially produced anti-EGFR antibody having specific binding capacity to EGFR which is characterized in that an epitope therefor is in a cysteine-rich subdomain 2 (C2 domain) and/or in a ligand-binding domain 1 (L1 domain) among four subdomains contained in the extracellular domain of EGFR.
    Type: Grant
    Filed: June 3, 2011
    Date of Patent: May 12, 2015
    Assignees: Toagosei Co. Ltd., Keio University
    Inventors: Nobuyoshi Shimizu, Atsushi Takayanagi, Tetsuhiko Yoshida
  • Anti-FLT3 antibodies
    Patent number: 9023996
    Abstract: The present invention relates to anti-FLT3 antibodies with a modified Fc region comprising the amino acid substitutions 239D and 332E to enhance antibody-dependent cell cytotoxicity (ADCC) of these antibodies. The invention further relates to pharmaceutical compositions containing these antibodies, nucleic acids encoding these antibodies as well as methods of using such antibodies.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: May 5, 2015
    Assignee: Synimmune GmbH
    Inventors: Ludger Grosse-Hovest, Hans-Joerg Buehring, Martin Hofmann, Steffen Aulwurm, Grundram Jung
  • High affinity human antibodies to human angiopoietin-2
    Patent number: 8987420
    Abstract: The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: March 24, 2015
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Gavin Thurston, Christopher Daly
  • Methods for treating cancer by administering an anti-Ang-2 antibody
    Patent number: 8980268
    Abstract: The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: March 17, 2015
    Assignee: Regeneron Pharamceuticals, Inc.
    Inventors: Israel Lowy, Gavin Thurston, Christopher Daly
  • Fusion protein capable of binding VEGF-A and TNF-alpha
    Patent number: 8927232
    Abstract: The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and TNF polypeptide comprising: (a) a nucleotide sequence encoding a TNFR2 component and VEGFR1 component operatively linked to (b) a nucleotide sequence encoding a multimerizing component, wherein the TNFR2 component consists essentially of a nucleotide sequence encoding the amino acid sequences of cystein rich domain 1, cystein rich domain 2, cystein rich domain 3, and cystein rich domain 4 of the extracellular domain of TNFR2, and wherein the VEGFR1 component consists essentially of a nucleotide sequence encoding the amino acid sequences of Ig-like domain 2 of the extracellular domain of VEGFR1.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: January 6, 2015
    Assignee: Korea Advanced Institute of Science and Technology (KAIST)
    Inventors: Keehoon Jung, Young Jun Koh, Gyun Min Lee, Sun Chang Kim, Gou Young Koh
  • Assay for anti-EGFRvIII antibodies
    Patent number: 8900816
    Abstract: Detection of human antibodies directed against the tumor-specific protein Epidermal Growth Factor Receptor variant Class III (EGFRvIII) provide information on tumor burden and vaccine response. The methods of the invention permit the specific identification of antibodies that are able to bind to EGFRvIII. The methods are useful in determining the presence of an EGFRvIII-expressing tumor and in detecting immune responses following immunization with EGFRvIII-derived peptide as part of a cancer immunotherapy regimen.
    Type: Grant
    Filed: July 21, 2008
    Date of Patent: December 2, 2014
    Assignee: Duke University
    Inventors: Robert J. Schmittling, Gary E. Archer, John H. Sampson, Darell D. Bigner